Yusuke Okamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yusuke Okamoto has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Akifumi Takaori-Kondo
Department of Hematology, Graduate School of Medicine, Kyoto University , Yoshidakonoe-cho, Sakyo-ku, Kyoto 606-8303
4 shared publications- Akifumi Takaori-Kondo
Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
4 shared publications - Minoru Takata
Laboratory of DNA Damage Signaling, Department of Late Effects Studies, Radiation Biology Center, Graduate School of Biostudies, Kyoto University, Kyoto, Japan; Multilayer Network Research Unit, Research Coordination Alliance, Kyoto University, Kyoto, Japan
4 shared publications Hironori Haga
Department of Diagnostic Pathology, Kyoto University Hospital , 54 Shogoin-kawahara-cho, Sakyoku, Kyoto 606-8507
2 shared publications- Kotaro Shirakawa
Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto 606-8303, Japan
2 shared publications Kouhei Yamashita
Department of Hematology, Graduate School of Medicine, Kyoto University , Yoshidakonoe-cho, Sakyo-ku, Kyoto 606-8303
2 shared publications
Latest Publications
- Open Access
- 13 October 2026
- Published by Springer Nature in Annals of Hematology
Pomalidomide successfully treated transfusion-dependent epistaxis in hereditary hemorrhagic telangiectasia: a case report
- 13 October 2026
- Published by Springer Nature in Annals of Hematology
Open AccessPomalidomide successfully treated transfusion-dependent epistaxis in hereditary hemorrhagic telangiectasia: a case report
- Open Access
- 9 September 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (9) , 1310
Replication Stress Tolerance in Adult T-Cell Leukemia
Replication stress (RS) represents a major vulnerability of cancer cells treated with nucleoside analogs and related antimetabolites; however, tumors frequently acquire tolerance mechanisms that permit survival despite persistent DNA lesions. This review examines molecular determinants of RS tolerance, focusing on human T-cell leukemia virus type 1 (HTLV-1)-mediated adult T-cell leukemia/lymphoma (ATL) as a model of virus-mediated rewiring of DNA damage responses. Chain-terminating nucleoside analogs generate aberrant replication intermediates, including blocked 3’ DNA termini, mis-incorporated bases, and stalled replication forks. In ATL, viral oncoproteins suppress key components of replication stress response pathways, notably tyrosyl-DNA phosphodiesterase 1 (TDP1) and mismatch repair (MMR), thereby creating exploitable repair deficiencies. Consistent with this vulnerability, ATL cells exhibit marked sensitivity to replication stress–inducing agents such as irinotecan (CPT-11) and the chain-terminating nucleoside analog abacavir. Recent CRISPR-based functional genomics studies further identify Schlafen 11 (SLFN11) as an independent and dominant regulator of RS sensitivity. SLFN11 determines the fate of stressed replication forks independently of lesion processing, acting as an execution factor that converts otherwise tolerable RS into irreversible replication arrest. We conclude by discussing therapeutic strategies that exploit RS tolerance defects in ATL, including biomarker-guided nucleoside analog therapy, and rational combination approaches targeting compensatory RS pathways.
- 9 September 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (9) , 1310
Open AccessReplication Stress Tolerance in Adult T-Cell Leukemia
Replication stress (RS) represents a major vulnerability of cancer cells treated with nucleoside analogs and related antimetabolites; however, tumors frequently acquire tolerance mechanisms that permit survival despite persistent DNA lesions. This review examines molecular determinants of RS tolerance, focusing on human T-cell leukemia virus type 1 (HTLV-1)-mediated adult T-cell leukemia/lymphoma (ATL) as a model of virus-mediated rewiring of DNA damage responses. Chain-terminating nucleoside analogs generate aberrant replication intermediates, including blocked 3’ DNA termini, mis-incorporated bases, and stalled replication forks. In ATL, viral oncoproteins suppress key components of replication stress response pathways, notably tyrosyl-DNA phosphodiesterase 1 (TDP1) and mismatch repair (MMR), thereby creating exploitable repair deficiencies. Consistent with this vulnerability, ATL cells exhibit marked sensitivity to replication stress–inducing agents such as irinotecan (CPT-11) and the chain-terminating nucleoside analog abacavir. Recent CRISPR-based functional genomics studies further identify Schlafen 11 (SLFN11) as an independent and dominant regulator of RS sensitivity. SLFN11 determines the fate of stressed replication forks independently of lesion processing, acting as an execution factor that converts otherwise tolerable RS into irreversible replication arrest. We conclude by discussing therapeutic strategies that exploit RS tolerance defects in ATL, including biomarker-guided nucleoside analog therapy, and rational combination approaches targeting compensatory RS pathways.
- Open Access
- 10 August 2026
- Published by MDPI AG in Preprints.org
Replication Stress Tolerance in Adult T-Cell Leukemia
Replication stress (RS) represents a major vulnerability of cancer cells treated with nu-cleoside analogs and related antimetabolites; however, tumors frequently acquire tol-erance mechanisms that permit survival despite persistent DNA lesions. This review examines molecular determinants of RS tolerance, focusing on human T-cell leukemia virus type 1 (HTLV-1)–mediated adult T-cell leukemia/lymphoma (ATL) as a model of virus-mediated rewiring of DNA damage responses. Chain-terminating nucleoside an-alogs generate aberrant replication intermediates, including blocked 3’ DNA termini, mis-incorporated bases, and stalled replication forks. In ATL, viral oncoproteins suppress key components of replication stress response pathways, notably tyrosyl-DNA phos-phodiesterase 1 (TDP1) and mismatch repair (MMR), thereby creating exploitable repair deficiencies. Consistent with this vulnerability, ATL cells exhibit marked sensitivity to replication stress–inducing agents such as irinotecan (CPT-11) and the chain-terminating nucleoside analog abacavir. Recent CRISPR-based functional genomics studies further identify Schlafen 11 (SLFN11) as an independent and dominant regulator of RS sensitivity. SLFN11 determines the fate of stressed replication forks independently of lesion pro-cessing, acting as an execution factor that converts otherwise tolerable RS into irreversible replication arrest. We conclude by discussing therapeutic strategies that exploit RS tol-erance defects in ATL, including biomarker-guided nucleoside analog therapy, and ra-tional combination approaches targeting compensatory RS pathways.
- 10 August 2026
- Published by MDPI AG in Preprints.org
Open AccessReplication Stress Tolerance in Adult T-Cell Leukemia
Replication stress (RS) represents a major vulnerability of cancer cells treated with nu-cleoside analogs and related antimetabolites; however, tumors frequently acquire tol-erance mechanisms that permit survival despite persistent DNA lesions. This review examines molecular determinants of RS tolerance, focusing on human T-cell leukemia virus type 1 (HTLV-1)–mediated adult T-cell leukemia/lymphoma (ATL) as a model of virus-mediated rewiring of DNA damage responses. Chain-terminating nucleoside an-alogs generate aberrant replication intermediates, including blocked 3’ DNA termini, mis-incorporated bases, and stalled replication forks. In ATL, viral oncoproteins suppress key components of replication stress response pathways, notably tyrosyl-DNA phos-phodiesterase 1 (TDP1) and mismatch repair (MMR), thereby creating exploitable repair deficiencies. Consistent with this vulnerability, ATL cells exhibit marked sensitivity to replication stress–inducing agents such as irinotecan (CPT-11) and the chain-terminating nucleoside analog abacavir. Recent CRISPR-based functional genomics studies further identify Schlafen 11 (SLFN11) as an independent and dominant regulator of RS sensitivity. SLFN11 determines the fate of stressed replication forks independently of lesion pro-cessing, acting as an execution factor that converts otherwise tolerable RS into irreversible replication arrest. We conclude by discussing therapeutic strategies that exploit RS tol-erance defects in ATL, including biomarker-guided nucleoside analog therapy, and ra-tional combination approaches targeting compensatory RS pathways.
- Open Access
- 9 May 2026
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2026 (5)
A diagnostic pitfall in cold agglutinin disease: KMT2D-mutated CAD-associated lymphoproliferative disorder with a CLL-like immunophenotype
Cold agglutinin disease (CAD) is an uncommon hemolytic anemia by complement-fixing IgM autoantibodies and is frequently associated with a distinct clonal B-cell lymphoproliferative disorder (CAD-LPD). We report a woman in her 50’s with progressive fatigue who presented with hemolytic anemia and an IgM-κ paraprotein. Bone marrow examination revealed a small clonal B-cell population (5.8%) with a CLL-like immunophenotype. Despite the absence of peripheral lymphocytosis or established treatment indications for chronic lymphocytic leukemia (CLL), B-cell–directed therapy, including ibrutinib and venetoclax plus rituximab, was administered over the course of approximately one year based on the initial diagnostic impression, but failed to control hemolysis. Targeted next-generation sequencing identified a KMT2D frameshift mutation, supporting a diagnosis of CAD-LPD rather than monoclonal B-cell lymphocytosis. Subsequent treatment with the C1s inhibitor sutimlimab resulted in sustained resolution of hemolysis. This case highlights diagnostic pitfalls in CAD and underscores the value of molecular profiling in guiding appropriate therapy.
- 9 May 2026
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2026 (5)
Open AccessA diagnostic pitfall in cold agglutinin disease: KMT2D-mutated CAD-associated lymphoproliferative disorder with a CLL-like immunophenotype
Cold agglutinin disease (CAD) is an uncommon hemolytic anemia by complement-fixing IgM autoantibodies and is frequently associated with a distinct clonal B-cell lymphoproliferative disorder (CAD-LPD). We report a woman in her 50’s with progressive fatigue who presented with hemolytic anemia and an IgM-κ paraprotein. Bone marrow examination revealed a small clonal B-cell population (5.8%) with a CLL-like immunophenotype. Despite the absence of peripheral lymphocytosis or established treatment indications for chronic lymphocytic leukemia (CLL), B-cell–directed therapy, including ibrutinib and venetoclax plus rituximab, was administered over the course of approximately one year based on the initial diagnostic impression, but failed to control hemolysis. Targeted next-generation sequencing identified a KMT2D frameshift mutation, supporting a diagnosis of CAD-LPD rather than monoclonal B-cell lymphocytosis. Subsequent treatment with the C1s inhibitor sutimlimab resulted in sustained resolution of hemolysis. This case highlights diagnostic pitfalls in CAD and underscores the value of molecular profiling in guiding appropriate therapy.
- 1 March 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 123 (4) , 469-470
Acute diplopia caused by extramedullary multiple myeloma
- 1 March 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 123 (4) , 469-470
Acute diplopia caused by extramedullary multiple myeloma
- Open Access
- 26 February 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (4)
Hemostatic rescue with rFVIIa in Bernard–Soulier syndrome refractory to HLA-matched platelet transfusion
We report the case of a man in his 50’s diagnosed with Bernard-Soulier syndrome (BSS) in childhood who developed refractory gluteal bleeding following a fall accident. The patient underwent four hematoma evacuation procedures and multiple platelet transfusions, including HLA (human leukocyte antigen) -matched platelet concentrates, without achieving sustained hemostatic control. Given the lack of response to platelet transfusion and ongoing bleeding risk, Eptacog Alfa (recombinant activated factor VII; rFVIIa) was administered for 4 days, following the dosing regimen recommended for Glanzmann thrombasthenia in surgical bleeding settings. Hemostasis was achieved shortly after rFVIIa administration, and no further surgical evacuation was necessary. Importantly, no thromboembolic complications occurred despite the use of rFVIIa. This case demonstrates that rFVIIa can serve as an effective adjunctive hemostatic therapy in patients with BSS who are refractory to platelet transfusions. We reviewed the existing literature on rFVIIa use in patients with BSS and summarized the clinical contexts, dosing strategies, efficacy, and safety outcomes. Our experience suggests that early consideration of rFVIIa may help prevent repeated surgical interventions and reduce bleeding-related morbidity in complex cases.
- 26 February 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (4)
Open AccessHemostatic rescue with rFVIIa in Bernard–Soulier syndrome refractory to HLA-matched platelet transfusion
We report the case of a man in his 50’s diagnosed with Bernard-Soulier syndrome (BSS) in childhood who developed refractory gluteal bleeding following a fall accident. The patient underwent four hematoma evacuation procedures and multiple platelet transfusions, including HLA (human leukocyte antigen) -matched platelet concentrates, without achieving sustained hemostatic control. Given the lack of response to platelet transfusion and ongoing bleeding risk, Eptacog Alfa (recombinant activated factor VII; rFVIIa) was administered for 4 days, following the dosing regimen recommended for Glanzmann thrombasthenia in surgical bleeding settings. Hemostasis was achieved shortly after rFVIIa administration, and no further surgical evacuation was necessary. Importantly, no thromboembolic complications occurred despite the use of rFVIIa. This case demonstrates that rFVIIa can serve as an effective adjunctive hemostatic therapy in patients with BSS who are refractory to platelet transfusions. We reviewed the existing literature on rFVIIa use in patients with BSS and summarized the clinical contexts, dosing strategies, efficacy, and safety outcomes. Our experience suggests that early consideration of rFVIIa may help prevent repeated surgical interventions and reduce bleeding-related morbidity in complex cases.
- 19 December 2025
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (1) , 102901
Parvovirus B19 infection induces pure red cell aplasia after lung transplantation
- 19 December 2025
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (1) , 102901
Parvovirus B19 infection induces pure red cell aplasia after lung transplantation
- Open Access
- 21 January 2021
- Published by American Society of Hematology in Blood
- Vol. 137 (3) , 336-348
SLFN11 promotes stalled fork degradation that underlies the phenotype in Fanconi anemia cells
Fanconi anemia (FA) is a hereditary disorder caused by mutations in any 1 of 22 FA genes. The disease is characterized by hypersensitivity to interstrand crosslink (ICL) inducers such as mitomycin C (MMC). In addition to promoting ICL repair, FA proteins such as RAD51, BRCA2, or FANCD2 protect stalled replication forks from nucleolytic degradation during replication stress, which may have a profound impact on FA pathophysiology. Recent studies showed that expression of the putative DNA/RNA helicase SLFN11 in cancer cells correlates with cell death on chemotherapeutic treatment. However, the underlying mechanisms of SLFN11-mediated DNA damage sensitivity remain unclear. Because SLFN11 expression is high in hematopoietic stem cells, we hypothesized that SLFN11 depletion might ameliorate the phenotypes of FA cells. Here we report that SLFN11 knockdown in the FA patient-derived FANCD2-deficient PD20 cell line improved cell survival on treatment with ICL inducers. FANCD2−/−SLFN11−/− HAP1 cells also displayed phenotypic rescue, including reduced levels of MMC-induced chromosome breakage compared with FANCD2−/− cells. Importantly, we found that SLFN11 promotes extensive fork degradation in FANCD2−/− cells. The degradation process is mediated by the nucleases MRE11 or DNA2 and depends on the SLFN11 ATPase activity. This observation was accompanied by an increased RAD51 binding at stalled forks, consistent with the role of RAD51 antagonizing nuclease recruitment and subsequent fork degradation. Suppression of SLFN11 protects nascent DNA tracts even in wild-type cells. We conclude that SLFN11 destabilizes stalled replication forks, and this function may contribute to the attrition of hematopoietic stem cells in FA.
- 21 January 2021
- Published by American Society of Hematology in Blood
- Vol. 137 (3) , 336-348
Open AccessSLFN11 promotes stalled fork degradation that underlies the phenotype in Fanconi anemia cells
Fanconi anemia (FA) is a hereditary disorder caused by mutations in any 1 of 22 FA genes. The disease is characterized by hypersensitivity to interstrand crosslink (ICL) inducers such as mitomycin C (MMC). In addition to promoting ICL repair, FA proteins such as RAD51, BRCA2, or FANCD2 protect stalled replication forks from nucleolytic degradation during replication stress, which may have a profound impact on FA pathophysiology. Recent studies showed that expression of the putative DNA/RNA helicase SLFN11 in cancer cells correlates with cell death on chemotherapeutic treatment. However, the underlying mechanisms of SLFN11-mediated DNA damage sensitivity remain unclear. Because SLFN11 expression is high in hematopoietic stem cells, we hypothesized that SLFN11 depletion might ameliorate the phenotypes of FA cells. Here we report that SLFN11 knockdown in the FA patient-derived FANCD2-deficient PD20 cell line improved cell survival on treatment with ICL inducers. FANCD2−/−SLFN11−/− HAP1 cells also displayed phenotypic rescue, including reduced levels of MMC-induced chromosome breakage compared with FANCD2−/− cells. Importantly, we found that SLFN11 promotes extensive fork degradation in FANCD2−/− cells. The degradation process is mediated by the nucleases MRE11 or DNA2 and depends on the SLFN11 ATPase activity. This observation was accompanied by an increased RAD51 binding at stalled forks, consistent with the role of RAD51 antagonizing nuclease recruitment and subsequent fork degradation. Suppression of SLFN11 protects nascent DNA tracts even in wild-type cells. We conclude that SLFN11 destabilizes stalled replication forks, and this function may contribute to the attrition of hematopoietic stem cells in FA.
- 1 March 2019
- Published by Oxford University Press (OUP) in The Journal of Biochemistry
- Vol. 165 (6) , 465-470
Regulation of R-loops and genome instability in Fanconi anemia
Fanconi anemia (FA) is a devastating hereditary disorder with impaired genome stability resulting in physical abnormalities, gradual loss of hematopoietic stem cells and development of tumours and leukaemia. It has been suggested that functions of FA genes are required to maintain genome stability by counteracting endogenous metabolites, such as aldehydes, that damage DNA and stall replication forks. Recent studies have implicated co-transcriptional R-loops, consisting of a DNA:RNA hybrid and displaced single-stranded DNA, as one of the potential endogenous sources that induce genome instability and the FA phenotype. This review focuses on recent literature, including our own, regarding the interplay between FA proteins and R-loops, and will provide readers with a concise summary of this rapidly evolving field.
- 1 March 2019
- Published by Oxford University Press (OUP) in The Journal of Biochemistry
- Vol. 165 (6) , 465-470
Regulation of R-loops and genome instability in Fanconi anemia
Fanconi anemia (FA) is a devastating hereditary disorder with impaired genome stability resulting in physical abnormalities, gradual loss of hematopoietic stem cells and development of tumours and leukaemia. It has been suggested that functions of FA genes are required to maintain genome stability by counteracting endogenous metabolites, such as aldehydes, that damage DNA and stall replication forks. Recent studies have implicated co-transcriptional R-loops, consisting of a DNA:RNA hybrid and displaced single-stranded DNA, as one of the potential endogenous sources that induce genome instability and the FA phenotype. This review focuses on recent literature, including our own, regarding the interplay between FA proteins and R-loops, and will provide readers with a concise summary of this rapidly evolving field.
- Open Access
- 15 November 2018
- Published by Wiley in The FEBS Journal
- Vol. 286 (1) , 139-150
FANCD2 protects genome stability by recruiting RNA processing enzymes to resolve R‐loops during mild replication stress
R‐loops, which consist of DNA : RNA hybrids and displaced single‐strand DNA, are a major threat to genome stability. We have previously reported that a key Fanconi anemia protein, FANCD2, accumulates on large fragile genes during mild replication stress in a manner depending on R‐loops. In this study, we found that FANCD2 suppresses R‐loop levels. Furthermore, we identified FANCD2 interactions with RNA processing factors, including hnRNP U and DDX47. Our data suggest that FANCD2, which accumulates with R‐loops in chromatin, recruits these factors and thereby promotes efficient processing of long RNA transcripts. This may lead to a reduction in transcription–replication collisions, as detected by PLA between PCNA and RNA Polymerase II, and hence, lowered R‐loop levels. We propose that this mechanism might contribute to maintenance of genome stability during mild replication stress.
- 15 November 2018
- Published by Wiley in The FEBS Journal
- Vol. 286 (1) , 139-150
Open AccessFANCD2 protects genome stability by recruiting RNA processing enzymes to resolve R‐loops during mild replication stress
R‐loops, which consist of DNA : RNA hybrids and displaced single‐strand DNA, are a major threat to genome stability. We have previously reported that a key Fanconi anemia protein, FANCD2, accumulates on large fragile genes during mild replication stress in a manner depending on R‐loops. In this study, we found that FANCD2 suppresses R‐loop levels. Furthermore, we identified FANCD2 interactions with RNA processing factors, including hnRNP U and DDX47. Our data suggest that FANCD2, which accumulates with R‐loops in chromatin, recruits these factors and thereby promotes efficient processing of long RNA transcripts. This may lead to a reduction in transcription–replication collisions, as detected by PLA between PCNA and RNA Polymerase II, and hence, lowered R‐loop levels. We propose that this mechanism might contribute to maintenance of genome stability during mild replication stress.